<DOC>
	<DOCNO>NCT00044382</DOCNO>
	<brief_summary>To estimate percent patient myelodysplastic syndrome ( MDS ) experience erythroid response interval response daily treatment 25 mg CC-5013 .</brief_summary>
	<brief_title>Study Safety Efficacy CC-5013 Treatment For Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Diagnosis de novo myelodysplastic syndrome least 12 week duration . Baseline mean hemoglobin &lt; 10.0 g/dL ( untransfused ) and/or transfusion dependent define require least 4 unit RBC 8 week prior baseline . More 30 day must elapse since previous treatment MDS , transfusion . Women must pregnant lactate No use another experimental study drug within 30 dy\ays baseline Understand sign write informed consent Able adhere study visit schedule , understand comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Revimid</keyword>
	<keyword>CC5013</keyword>
	<keyword>CC-5013</keyword>
</DOC>